{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T10:10:17Z","timestamp":1783937417954,"version":"3.55.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","contraceptionjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.contraception.2018.02.008","type":"journal-article","created":{"date-parts":[[2018,3,26]],"date-time":"2018-03-26T12:42:43Z","timestamp":1522068163000},"page":"1-3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Heavy menstrual bleeding: is tranexamic acid a safe adjunct to combined hormonal contraception?"],"prefix":"10.1016","volume":"98","author":[{"given":"JG","family":"Thorne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PD","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RL","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.contraception.2018.02.008_bb0005","first-page":"503","article-title":"Daily menstrual blood loss and quality of life in women with heavy menstrual bleeding","volume":"8","author":"Lukes","year":"2012","journal-title":"Womens Health"},{"issue":"5 e-Suppl","key":"10.1016\/j.contraception.2018.02.008_bb0010","first-page":"S1","article-title":"Abnormal uterine bleeding in premenopausal woman. SOGC Clinical Practice Guideline 292","volume":"35","author":"Singh","year":"2013","journal-title":"J Obstet Gynecol Can"},{"key":"10.1016\/j.contraception.2018.02.008_bb0015","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000400.pub3","article-title":"Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding","author":"Lethaby","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.contraception.2018.02.008_bb0020","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/AOG.0b013e3182118ac3","article-title":"Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: a randomized controlled trial","volume":"117","author":"Jensen","year":"2011","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2018.02.008_bb0025","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.bpobgyn.2007.03.023","article-title":"Modern management of abnormal uterine bleeding\u2014the levonorgestrel intra-uterine system","volume":"21","author":"Mansour","year":"2007","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.contraception.2018.02.008_bb0030","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1111\/j.1471-0528.1980.tb04489.x","article-title":"Reduction of menstrual blood loss by danazol in unexplained menorrhagia: lack of effect of placebo","volume":"87","author":"Chimbira","year":"1980","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.contraception.2018.02.008_bb0035","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/AOG.0b013e3181f20177","article-title":"Tranexamic acid treatment for heavy menstrua lbleeding: a randomized controlled trial","volume":"116","author":"Lukes","year":"2010","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2018.02.008_bb0040","first-page":"285","article-title":"Use of intravenous Premarin in the treatment of dysfunctional uterine bleeding\u2014a double-blind randomized controlled study","volume":"59","author":"DeVore","year":"1982","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2018.02.008_bb0045","doi-asserted-by":"crossref","first-page":"499.e1","DOI":"10.1016\/j.ajog.2013.02.013","article-title":"A new progestogen-only medical therapy for outpatient management of acute, abnormal uterine bleeding: a pilot study","volume":"208","author":"Ammerman","year":"2013","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.contraception.2018.02.008_bb0050","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1097\/01.AOG.0000238343.62063.22","article-title":"Oral medroxyprogesterone acetate and combination oral contraceptives for acute uterine bleeding. A Randomized Controlled Trial","volume":"108","author":"Munro","year":"2006","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2018.02.008_bb0055","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/0002-9378(94)90466-9","article-title":"Cyclic changes in endometrial tissue plasminogen activator and plasminogen activator inhibitor type 1 in women with normal menstruation and essential menorrhagia","volume":"171","author":"Gleeson","year":"1994","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.contraception.2018.02.008_bb0060","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2165\/00002018-200831030-00003","article-title":"A benefit-risk review of systemic haemostatic agents. Part 1: in major surgery","volume":"31","author":"Fraser","year":"2008","journal-title":"Drug Saf"},{"issue":"2","key":"10.1016\/j.contraception.2018.02.008_bb0065","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1055\/s-0038-1649475","article-title":"Treatment with tranexamic acid during pregnancy and the risk of thrombo-embolic events","volume":"70","author":"Lindoff","year":"1993","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.contraception.2018.02.008_bb0070","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/ijgo.12047","article-title":"A systematic review and meta-analysis of the effect of prophylactic tranexamic acid treatment in major benign uterine surgery","volume":"136","author":"Topsoee","year":"2017","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.contraception.2018.02.008_bb0075","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ccc.2016.08.004","article-title":"Tranexamic acid update in trauma","volume":"33","author":"Ramirez","year":"2017","journal-title":"Crit Care Clin"},{"key":"10.1016\/j.contraception.2018.02.008_bb0080","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/S0140-6736(17)30638-4","article-title":"Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial","volume":"389","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2018.02.008_bb0085","author":"Moberly"},{"key":"10.1016\/j.contraception.2018.02.008_bb0090","series-title":"UK public assessment report [online]","article-title":"Cyclo-F 500mg film-coated tablets: Tranexamic acid","author":"Medicines and Healthcare products Regulatory Agency","year":"2010"},{"key":"10.1016\/j.contraception.2018.02.008_bb0105","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(76)93013-0","article-title":"Case report: Tranexamic acid and intracranial thrombosis","volume":"2","author":"Rydin","year":"1976","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2018.02.008_bb0110","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/j.1471-0528.1982.tb04727.x","article-title":"Case report: Tranexamic acid, intrauterine contraceptive devices and fatal cerebral thrombosis","volume":"89","author":"Agnelli","year":"1982","journal-title":"Brit J Obstet Gynaecol"},{"key":"10.1016\/j.contraception.2018.02.008_bb0115","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/00006982-199001030-00005","article-title":"Central venous stasis retinopathy following the use of tranexamic acid","volume":"10","author":"Snir","year":"1990","journal-title":"Retina"},{"key":"10.1016\/j.contraception.2018.02.008_bb0120","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s10157-003-0254-y","article-title":"Tranexamic acid-induced visual impairment in a hemodialysis patient","volume":"7","author":"Kitamura","year":"2003","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.contraception.2018.02.008_bb0125","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/0002-9394(88)90069-4","article-title":"Retinal artery occlusion associated with tranexamic acid therapy","volume":"105","author":"Parsons","year":"1988","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.contraception.2018.02.008_bb0130","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1023\/B:CARD.0000033646.21346.e4","article-title":"Combined treatment with tranexamic acid and oral contraceptive pill causes coronary ulcerated plaque and acute myocardial infarction","volume":"18","author":"Iacobellis","year":"2004","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.contraception.2018.02.008_bb0135","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1055\/s-0037-1616122","article-title":"No increased risk of venous thrombosis in women taking tranexamic acid","volume":"86","author":"Berntorp","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.contraception.2018.02.008_bb0140","first-page":"1","article-title":"Tranexamic acid therapy: effective in treatment in heavy menstrual bleeding: Clinical update on safety","volume":"4","author":"Rybo","year":"1991","journal-title":"Ther Adv"},{"issue":"5","key":"10.1016\/j.contraception.2018.02.008_bb0145","first-page":"591","article-title":"Safety of tranexamic acid in women with heavy menstrual bleeding: an open-label extension study","volume":"7","author":"Lukes","year":"2011","journal-title":"Womens Health"},{"key":"10.1016\/j.contraception.2018.02.008_bb0150","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/00001648-200107000-00016","article-title":"Increased risks of circulatory diseases in late pregnancy and puerperium","volume":"12","author":"Ros","year":"2001","journal-title":"Epidemiology"},{"key":"10.1016\/j.contraception.2018.02.008_bb0155","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2008.02921.x","article-title":"Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study","volume":"6","author":"Pomp","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.contraception.2018.02.008_bb0160","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2165\/00002018-200831040-00001","article-title":"Benefit-risk review of systemic haemostatic agents part 2: in excessive or heavy menstrual bleeding","volume":"31","author":"Fraser","year":"2008","journal-title":"Drug Saf"},{"key":"10.1016\/j.contraception.2018.02.008_bb0165","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3109\/00016349009036161","article-title":"Treatment with the fibrinolytic inhibitor tranexamic acid: risk for thrombosis","volume":"69","author":"Bekassy","year":"1990","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.contraception.2018.02.008_bb0170","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.contraception.2006.12.018","article-title":"Range of published estimates of venous thromboembolism incidence in young women","volume":"75","author":"Heinemann","year":"2007","journal-title":"Contraception"},{"issue":"3","key":"10.1016\/j.contraception.2018.02.008_bb0175","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1783\/147118910791749425","article-title":"Oral contraceptives and venous thromboembolism consensus opinion from an international workshop held in Berlin, Germany in December 2009","volume":"36","author":"Reid","year":"2010","journal-title":"J Fam Plann Reprod Health Care"},{"key":"10.1016\/j.contraception.2018.02.008_bb0180","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.contraception.2014.02.002","article-title":"Oral hormonal contraception and venous thromboembolism","volume":"89","author":"Reid","year":"2014","journal-title":"Contraception"},{"issue":"10","key":"10.1016\/j.contraception.2018.02.008_bb0185","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1111\/1471-0528.14623","article-title":"Drospirenone-containing oral contraceptive pills and the risk of venous thromboembolism: a systematic review of observational studies","volume":"124","author":"Lariv\u00e9e","year":"2017","journal-title":"BJOG"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782418300702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782418300702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T20:12:18Z","timestamp":1757880738000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782418300702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0010782418300702"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2018.02.008","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heavy menstrual bleeding: is tranexamic acid a safe adjunct to combined hormonal contraception?","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2018.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}